Herd immunity or suppression strategy to combat COVID-19

被引:23
|
作者
Jung, F. [1 ]
Krieger, V. [2 ]
Hufert, F. T. [3 ,4 ]
Kuepper, J. -H. [1 ,4 ]
机构
[1] Brandenburg Tech Univ Cottbus, Inst Biotechnol, Mol Cell Biol, Senftenberg, Germany
[2] TMM AG Boblingen, Dept Head Lab Planning & Norming Informat Managem, Boblingen, Germany
[3] Brandenburg Med Sch, Inst Microbiol & Virol, Senftenberg, Germany
[4] Brandenburg Med Sch Theodor Fontane & Univ Potsda, Joint Fac Brandenburg Univ Technol Cottbus Senfte, Fac Hlth Sci, Potsdam, Germany
关键词
COVID-19; strategy; Sweden; Taiwan; Germany;
D O I
10.3233/CH-209006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Some months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Some states, such as the Netherlands, Germany, Great Britain, Sweden and the USA initially focused on keeping the restrictions for economy and society as low as possible. The responsible authorities were of the opinion - and still are e.g. in Sweden - that it is sufficient enough to protect particularly vulnerable persons such as the elderly or people with pre-existing conditions. The idea behind this is that as soon as 60 to 70 percent of the population is infected with a pathogen, a so-called "herd immunity" has developed. However, the increasing numbers of deaths and modelling studies showed the expected overload of the hospitals. Therefore, most countries decided for a temporary lockdown with the exception of Sweden. Based on the number of the total population, three times more people died from COVID-19 in Sweden (2679 deaths per 10 million inhabitants) compared to Germany (6848 deaths per 80 million inhabitants). The comparison Sweden versus Taiwan is even worse because 1072 times more people died in Sweden based on the number of the population (6 deaths per 24 million inhabitants). In the face of the lack of an antiviral treatment and the lack of a protective vaccine one must state Taiwan has made the best out of the pandemic situation whereas Sweden failed completely.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 50 条
  • [31] CURRENT STRATEGY TO COMBAT COVID-19 IN INDONESIA
    Adriana, D. N.
    Miftahussurur, M.
    NEW ARMENIAN MEDICAL JOURNAL, 2020, 14 (04): : 16 - 28
  • [32] Critical interpretative synthesis of herd immunity for COVID-19 pandemic
    Garg, Suneela
    Singh, Meghachandra M.
    Deshmukh, Chetana Prakash
    Bhatnagar, Nidhi
    Borle, Amod L.
    Kumar, Raman
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (03) : 1117 - 1123
  • [33] Is COVID-19 Herd Immunity Influenced by Population Densities of Cities?
    Arbel, Yuval
    Arbel, Yifat
    Kerner, Amichai
    Kerner, Miryam
    SUSTAINABILITY, 2022, 14 (16)
  • [34] Can India develop herd immunity against COVID-19?
    Gowrisankar, A.
    Rondoni, Lamberto
    Banerjee, Santo
    EUROPEAN PHYSICAL JOURNAL PLUS, 2020, 135 (06):
  • [35] Development of Herd Immunity to COVID-19 in Louisiana Nursing Homes
    Reilly, Thomas A.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2021, 22 (02) : 256 - 257
  • [36] COVID-19: Cross Reactive Immunity, Herd Immunity, and Convalescent Serum Therapy
    Ibrahim, Nahla Khamis
    Bagabir, Hala Abubaker A.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (47A) : 387 - 402
  • [37] Herd Immunity to Fight Against COVID-19: A Narrative Review
    Suryawanshi, Yasha N.
    Biswas, Dalia A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [38] COVID-19 natural herd immunity and risk of neuropsychiatric disorders
    Losilla-Rodriguez, Beatriz
    Maldonado, Natalia
    Moreno-Mellado, Elisa
    Lopez-Diaz, Alvaro
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2020, 13 (04): : 228 - 229
  • [39] Caveats on COVID-19 herd immunity threshold: the Spain case
    Garcia-Garcia, David
    Morales, Enrique
    Fonfria, Eva S.
    Vigo, Isabel
    Bordehore, Cesar
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [40] COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects
    Wong, Rebecca S. Y.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2021, 43 (02) : 203 - 217